Delfi Diagnostics Is A Biotechnology Company Based In Marylandfocused On Early Cancer Detection Through Advanced Genomic Analysis And Machine Learningthe Company Specializes In Next Generation Liquid Biopsy Technologies That Identify Cancer Associated Dna Fragmentation Patterns In Blood Sampleswith A Team Of 51 200 Employeesdelfi Aims To Make Cancer Screening Accessible And Effectiveparticularly For High Risk Populations The Company S Core Technology Includes A Fragmentomics Platform That Analyzes Millions Of Dna Fragments Using Whole Genome Sequencing And Machine Learningthis Allows For High Sensitivity Detection Of Multiple Cancer Types Through Blood Based Testswhich Are Designed To Be Integrated Into Routine Clinical Practicedelfi S Early Detection Tests Target Asymptomatic Cancerenhancing Screening Options For Individuals Who May Face Barriers To Traditional Methods Delfi Has Established Strategic Partnershipsincluding Collaborations With The Merck Global Health Innovation Fund And Incendia Therapeuticsto Support Its Growth And Commercialization Effortsthe Company Is Committed To Advancing Cancer Detection Methodologies And Has Been Recognized For Its Innovative Approach In Recent Industry Presentations
